Shots:

• The approval is based on P-II & P-III sustaIMM- ultIMMa-1 and IMMspire study results assessing Skyrizi in Japanese patients with plaque psoriasis- generalized pustular psoriasis and erythrodermic psoriasis & active psoriatic arthritis
• The study resulted in safe and effective results and has capabilities to improve the signs of these chronic immune-mediated diseases
• Skyrizi (risankizumab) is a humanized immunoglobulin G1 (IgG1) mAb inhibiting IL-23 and has received a positive opinion from the EMA’s CHMP for moderate to severe plaque psoriasis in adult patients in Feb- 2019 and currently under review with the US FDA

  Ref: AbbVie | Image: AbbVie